We are live on ! Find out more
CAPR icon

Capricor Therapeutics
CAPR

18 hedge funds and large institutions have $597K invested in Capricor Therapeutics in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

666% more capital inflows, than outflows

Capital inflows: $456K | Capital outflows: $59.5K

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

6% more funds holding

Funds holding: 17 → 18 (+1)

3.33% less ownership

Funds ownership: 5.86% → 2.53% (-3.3%)

Holders
18
Holders Change
+1
Holders Change %
+5.88%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$375K
2
Jane Street
Jane Street
New York
+$33.7K
3
Renaissance Technologies
Renaissance Technologies
New York
+$27.7K
4
Citadel Advisors
Citadel Advisors
Florida
+$17.4K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.41K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$52K
2
UBS Group
UBS Group
Switzerland
-$5.55K
3
Deutsche Bank
Deutsche Bank
Germany
-$2K

CAPR Hedge Fund Activity: Q1 2020 in Review

18 of the 4,549 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2020, worth a combined $597K — up 114% from $279K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CAPR positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $375K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $52K sold.

  • 18 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2020, up from 17 in Q4 2019.
  • Funds reported $597K of Capricor Therapeutics stock for Q1 2020, up 114% quarter-over-quarter.
  • 4 funds opened new Capricor Therapeutics positions in Q1 2020 and 2 closed out, a net change of +2 holders.
  • The largest Capricor Therapeutics buyer in Q1 2020 was Armistice Capital, an estimated $375K added.
  • The largest Capricor Therapeutics seller in Q1 2020 was Two Sigma Investments, an estimated $52K sold.

Based on aggregated 13F filings for Q1 2020.